• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov12
4D Molecular Therapeutics Receives Buy Rating from H.C. Wainwright Analyst
11:19
Nov11
Morgan Stanley Reiterates Hold Rating on 4D Molecular Therapeutics
12:23
4D Molecular Therapeutics released FY2025 Q3 earnings on November 10 (EST), actual revenue USD 90 K (forecast USD 403 K), actual EPS USD -1.0133 (forecast USD -0.9916)
04:00
4D Molecular Therapeutics released FY2025 9 Months Earnings on November 10, 2025, EST: Actual Revenue USD 119 K, Actual EPS USD -2.8512
04:00
Nov6
4D Molecular Therapeutics Announces Positive Mid-Stage Results for 4D-150 Gene Therapy Drug
11:36
Nov3
4D Molecular Therapeutics and Otsuka Enter into Exclusive License Agreement to Develop and Market Eye Drug
08:41

Schedules & Filings

Schedules
Filings
Nov10
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 90 K, Net Income -56.88 M, EPS -1.0133

Aug11
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 15 K, Net Income -54.66 M, EPS -0.9773

May8
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 14 K, Net Income -47.97 M, EPS -0.8605

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MSOX
7.940
+107.85%
+4.120
YCBD
1.200
+90.17%
+0.569
THH
15.520
+57.72%
+5.680
WEED
25.325
+55.65%
+9.055
NCI
1.920
+54.84%
+0.680
CNBS
34.820
+54.57%
+12.293
MSOS
5.800
+54.26%
+2.040
CGC
1.740
+53.98%
+0.610
RYM
23.800
+47.73%
+7.690
TLRY
12.150
+44.13%
+3.720
View More